Wedbush upgraded Arvinas to Outperform from Neutral with a price target of $24, down from $27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas presents interim data from Phase 1/2 clinical trial for bavdegalutamide
- Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
- Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023